Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

apadamtase alfa

A recombinant human form of a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) that may be used as a replacement therapy for ADAMTS13 with indirect anti-thrombotic and anti-thrombocytopenic activities. Upon administration, apadamtase alfa acts similarly as endogenous ADAMTS13 and mediates the cleavage of von Willebrand factor (VWF) at the Tyr1605-Met1606 bond in the A2 domain. The cleavage of ultralarge (UL) VWF multimers into smaller forms helps regulate the size of VWF multimers, preventing the binding of platelets to UL VWF and the resulting thrombotic thrombocytopenic purpura (TTP). ADAMTS13 plays a key role in the proteolysis of VWF multimers. VWF is involved in platelet adhesion and blood coagulation.
Synonym:rADAMTS13
recombinant a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13
recombinant a disintegrin and metalloproteinase with thrombospondin motifs 13
recombinant ADAMTS13
recombinant human ADAMTS-13
recombinant human ADAMTS13
Code name:BAX 930
BAX-930
BAX930
SHP 655
SHP-655
SHP655
TAK 755
TAK-755
TAK755
Search NCI's Drug Dictionary